Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.60 |
| ▸ | GABRR1 | P24046 | 5/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3898177 | 1.00 | GABBR1 (0.60) | GABBR1GABRR1GABBR2LPAR3LPAR2 | |
| SCHEMBL3894140 | 1.00 | GABBR1 (0.60) | GABBR1GABRR1GABBR2LPAR3LPAR2 | |
| SCHEMBL3892892 | 0.83 | GABBR1 (0.68) | GABBR1GABRR1 | |
| SCHEMBL3900351 | 0.76 | GABBR1 (1.00) | GABBR1GABRR1 | |
| SCHEMBL3897695 | 0.76 | GABBR1 (1.00) | GABBR1GABRR1 | |
| SCHEMBL4585698 | 0.73 | GABBR2 (0.41) | GABBR1GABRR1GABBR2LPAR3LPAR2 | |
| SCHEMBL31590613 | 0.73 | GABBR2 (0.38) | GABBR1GABRR1GABBR2LPAR3LPAR2 | |
| SCHEMBL3898966 | 0.72 | GABBR1 (0.56) | GABBR1GABRR1 | |
| SCHEMBL31590899 | 0.71 | LPAR3 (0.45) | LPAR3LPAR2CETP | |
| SCHEMBL13940010 | 0.71 | GABBR1 (0.69) | GABBR1GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773740-B1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | UNIV SYDNEY (AU) | 2009-02-18 | — | — | EP | disclosed |
| US-20080032950-A1 | Neurologically-Active Compounds | THE UNIVERSITY OF SYDNEY (AU) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032950-A1 | Neurologically-Active Compounds | GABRE, GABRA5, GABRA1 | GABBR1 20/4885GABRR1 14/4885GABBR2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.